AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced the completion of the facilit...
Charles River Laboratories International, Inc. announced the launch of its lentiviral vector (LVV) manufacturing platform, Lentivation™. The pl...
New sites at Darmstadt and Hamburg complement Merck’s global integrated mRNA service network with pre-clinical to commercial capabilities Company&...
"Swiss CDMO Lonza Announces CEO Departure by Mutual Agreement; Chairman Baehny Takes the Helm Again Temporarily" Lonza, the Swiss Contract Development and...
Thermo Fisher Scientific Inc., the world leader in serving science, today announced the Gibco CTS Detachable Dynabeads (CTS Detachable Dynabeads)*, its nex...
Enzene Biosciences, a subsidiary of Mumbai-India, based Alkem Laboratories, has announced the inauguration of its cutting-edge research and...
SpendEdge, a global leader in procurement market intelligence space recently connected with a large Europe-based pharma company focused on large and small ...
Adding Four New Independent Directors Appoints John Greisch as Executive Chair Establishes New Strategic and Operational Review Committee of the Board ...
Series C is led by Koch Disruptive Technologies and includes Bristol Myers Squibb, DFJ Growth, Willett Advisors and existing investors Eclipse, Dech...
Under the agreement, AGC Biologics will leverage its monoclonal antibody development and manufacturing experience to perform process transfer, process opti...
Under the collaboration, Boostimmune will have access to WuXi XDC's fully integrated, one-stop bioconjugate platform and extensive expertise in industry-le...
Reports Q2 2023 total revenues of $338M, above the prior guidance range, net loss of $261M and adjusted EBITDA of $56M Updates FY 2023 guidance and prov...
The GMP release of its first DS facility in China enhances WuXi Vaccines' capability in providing global partners with comprehensive end-to-end solutions, ...
Recorded Q2’23 consolidated revenue of KRW 866.2 billion Recorded Q2’23 consolidated operating profit of KRW 253.4 billion&nbs...
© 2025 Biopharma Boardroom. All Rights Reserved.
